Technical Data
MART-1 (Melanoma Antigen Recognized by T-cells 1, Melan-A)
MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1 and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum.

Suitable for use in Flow Cytometry, Immunoprecipitation, Western Blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
Immunoprecipitation (Denatured verified): 2ug/mg protein lysate. Use Protein A.
Western Blot: 0.5-1ug/ml for 2 hours at RT.
Immunohistochemistry (Formalin/paraffin): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at RT for 20 minutes. M2410-12 is preferred for this application.
Optimal dilutions to be determined by the researcher.

Positive Control:
CaC1 melanoma cells and melanomas

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
MabIgG2b,k0.N.396Affinity Purified
500ul-20CBlue IceHumanMouse
Recombinant human MART-1 protein. Cellular Localization: Cytoplasmic
Purified by Protein A affinity chromatography.
Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide. Also available without BSA and azide. See M2410X.
Recognizes human MART-1 at ~18kD. Labels melanomas and other tumors showing melanocytic differentiation. Does not label tumor cells of epithelial, lymphoid, glial or mesenchymal origin. Species Crossreactivity: Equine. Does not crossreact with mouse or rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Postovit, L.-M. et al., Stem Cells 24: 501-505 (2005). 2. Kulesa, P.M., PNAS 103: 3752-3757 (2006). General References: 1. Milani, V., et al., Int. Immunol. 17(3): 257-268 (2005). 2. Maliver, P., et al., J. Vet. Med. A. Physiol. Pathol. Clin. Med. 51(9-10): 413-415 (2004). 3. Kucher, C., et al., Am. J. Dermatopathol. 26(6): 452-457 (2004). 4. Chapatte, L., et al., J. Immunol. 173(10): 6033-6040 (2004). 5. Tiwari, R., et al., Peptides 25(11): 1865-1871 (2004). 6. Shabrawi-Caelen, L.E., et al., Am. J. Dermatopathol. 26(5): 364-366 (2004). 7. Kawakami, Y., et al., J. Immunol. Methods 202(1): 13-25 (1997). 8. Marincola, F.M., et al., J. Immunother. Emphasis Tumor Immunol. 19(3): 192-205 (1996).